{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:21:01Z","timestamp":1789597261679,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Weisman Family"},{"name":"Mr. Michael Burke"},{"name":"Mr. Michael Shmerling"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.schres.2017.04.009","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T02:15:15Z","timestamp":1492568115000},"page":"194-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes"],"prefix":"10.1016","volume":"192","author":[{"given":"Jiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-5927","authenticated-orcid":false,"given":"Akane","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-8845","authenticated-orcid":false,"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2017.04.009_bb0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/mp.2010.14","article-title":"Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs","volume":"16","author":"Adkins","year":"2011","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.04.009_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/ecp.11.16","article-title":"Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia","volume":"4","author":"Arranz","year":"2011","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.schres.2017.04.009_bb0015","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1517\/14656566.2015.1058780","article-title":"Lurasidone in the treatment of schizophrenia: a critical evaluation","volume":"16","author":"Bruijnzeel","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"issue":"7","key":"10.1016\/j.schres.2017.04.009_bb0020","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.biopsych.2011.02.015","article-title":"Genome-wide analysis shows increased frequency of copy number variation deletions in Dutch schizophrenia patients","volume":"70","author":"Buizer-Voskamp","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.04.009_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddq013","article-title":"SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles","author":"Castermans","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"7510","key":"10.1016\/j.schres.2017.04.009_bb0030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Consortium, S.W.G.o.t.P.G","year":"2014","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.schres.2017.04.009_bb0035","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.1523\/JNEUROSCI.0025-12.2012","article-title":"S-SCAM\/MAGI-2 is an essential synaptic scaffolding molecule for the GluA2-containing maintenance pool of AMPA receptors","volume":"32","author":"Danielson","year":"2012","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2017.04.009_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-012-2921-8","article-title":"Serotonin\u2013glutamate and serotonin\u2013dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins","volume":"225","author":"De Bartolomeis","year":"2013","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.schres.2017.04.009_bb0045","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/ajmg.b.31234","article-title":"Association of GRIN1 and GRIN2A-D with schizophrenia and genetic interaction with maternal herpes simplex virus-2 infection affecting disease risk","volume":"156","author":"Demontis","year":"2011","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"3","key":"10.1016\/j.schres.2017.04.009_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003348","article-title":"Power and predictive accuracy of polygenic risk scores","volume":"9","author":"Dudbridge","year":"2013","journal-title":"PLoS Genet."},{"issue":"12","key":"10.1016\/j.schres.2017.04.009_bb0055","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1176\/appi.ajp.2012.12020218","article-title":"Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms","volume":"169","author":"Fanous","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"19","key":"10.1016\/j.schres.2017.04.009_bb0060","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1093\/hmg\/dds240","article-title":"RBFOX1 regulates both splicing and transcriptional networks in human neuronal development","volume":"21","author":"Fogel","year":"2012","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.schres.2017.04.009_bb0065","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/mp.2014.56","article-title":"Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients","volume":"20","author":"Frank","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.04.009_bb0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FBP.0b013e3282f62d8c","article-title":"Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity","volume":"19","author":"Galici","year":"2008","journal-title":"Behav. Pharmacol."},{"issue":"7","key":"10.1016\/j.schres.2017.04.009_bb0075","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/ng.841","article-title":"The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain","volume":"43","author":"Gehman","year":"2011","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.schres.2017.04.009_bb0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.psc.2009.12.003","article-title":"The role of genetics in the etiology of schizophrenia","volume":"33","author":"Gejman","year":"2010","journal-title":"Psychiatr. Clin. N. Am."},{"issue":"10","key":"10.1016\/j.schres.2017.04.009_bb0085","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/GIM.0b013e3181863239","article-title":"Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study","volume":"10","author":"Grossman","year":"2008","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.schres.2017.04.009_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biopsych.2014.09.009","article-title":"The promise of psychiatric pharmacogenomics","volume":"77","author":"Hamilton","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"1-3","key":"10.1016\/j.schres.2017.04.009_bb0095","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.schres.2015.06.008","article-title":"Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study","volume":"166","author":"Harvey","year":"2015","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2017.04.009_bb0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00406-013-0395-2","article-title":"Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors","volume":"263","author":"Hasan","year":"2013","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2017.04.009_bb0105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","article-title":"The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats","volume":"338","author":"Horiguchi","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.schres.2017.04.009_bb0110","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/WNR.0b013e328352de40","article-title":"5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux","volume":"23","author":"Huang","year":"2012","journal-title":"Neuroreport"},{"issue":"6","key":"10.1016\/j.schres.2017.04.009_bb0115","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jnc.12512","article-title":"Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT) 2A and DA D2 antagonism and 5-HT1A partial agonism","volume":"128","author":"Huang","year":"2014","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.schres.2017.04.009_bb0120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.schres.2017.04.009_bb0125","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/npp.2014.65","article-title":"Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia","volume":"39","author":"Jenkins","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.schres.2017.04.009_bb0130","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.biopsych.2012.01.020","article-title":"MAGI1 copy number variation in bipolar affective disorder and schizophrenia","volume":"71","author":"Karlsson","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.04.009_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036836","article-title":"Common variants in MAGI2 gene are associated with increased risk for cognitive impairment in schizophrenic patients","volume":"7","author":"Koide","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.schres.2017.04.009_bb0140","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/mp.2008.56","article-title":"Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study","volume":"14","author":"Lavedan","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2017.04.009_bb0145","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.97","article-title":"A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia","volume":"5","author":"Le Clerc","year":"2015","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.04.009_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.schres.2011.08.007","article-title":"The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response","volume":"132","author":"Lett","year":"2011","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.schres.2017.04.009_bb0155","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.schres.2017.04.009_bb0160","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study","volume":"147","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2017.04.009_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study","volume":"147","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.04.009_bb0170","first-page":"82","article-title":"Olanzapine reversed brain gene expression changes induced by phencyclidine treatment in non-human primates","volume":"1","author":"Martin","year":"2015","journal-title":"Mol. Neuropsychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.04.009_bb0175","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/npp.2010.193","article-title":"Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia","volume":"36","author":"McClay","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2017.04.009_bb0180","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/mp.2009.89","article-title":"Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics","volume":"16","author":"McClay","year":"2011","journal-title":"Mol. Psychiatry"},{"issue":"21","key":"10.1016\/j.schres.2017.04.009_bb0185","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1113\/jphysiol.2009.178236","article-title":"Neurobeachin, a protein implicated in membrane protein traffic and autism, is required for the formation and functioning of central synapses","volume":"587","author":"Medrihan","year":"2009","journal-title":"J. Physiol."},{"issue":"12","key":"10.1016\/j.schres.2017.04.009_bb0190","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.biopsych.2011.08.009","article-title":"Copy number variants for schizophrenia and related psychotic disorders in Oceanic Palau: risk and transmission in extended pedigrees","volume":"70","author":"Melhem","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.04.009_bb0195","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"9","key":"10.1016\/j.schres.2017.04.009_bb0200","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2017.04.009_bb0205","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am. J. Psychiatr."},{"issue":"7","key":"10.1016\/j.schres.2017.04.009_bb0210","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2011.24","article-title":"Genetic regulation of Nrnx1 expression: an integrative cross-species analysis of schizophrenia candidate genes","volume":"1","author":"Mozhui","year":"2011","journal-title":"Transl. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.04.009_bb0215","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.schres.2017.04.009_bb0220","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.schres.2017.04.009_bb0225","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/ejhg.2008.264","article-title":"Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis","volume":"17","author":"Need","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.schres.2017.04.009_bb0230","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12035-011-8223-z","article-title":"Kalirin signaling: implications for synaptic pathology","volume":"45","author":"Penzes","year":"2012","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.schres.2017.04.009_bb0235","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am. J. Hum. Genet."},{"issue":"7256","key":"10.1016\/j.schres.2017.04.009_bb0240","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nature08185","article-title":"Common polygenic variation contributes to risk of schizophrenia and bipolar disorder","volume":"460","author":"Purcell","year":"2009","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.schres.2017.04.009_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000534","article-title":"Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions","volume":"5","author":"Raychaudhuri","year":"2009","journal-title":"PLoS Genet."},{"issue":"4","key":"10.1016\/j.schres.2017.04.009_bb0250","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2215-0366(15)00553-2","article-title":"Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach","volume":"3","author":"Ruderfer","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.04.009_bb0255","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.conb.2010.08.016","article-title":"Synaptic organizing complexes","volume":"21","author":"Siddiqui","year":"2011","journal-title":"Curr. Opin. Neurobiol."},{"issue":"7\u20138","key":"10.1016\/j.schres.2017.04.009_bb0260","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/hup.1146","article-title":"Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response","volume":"25","author":"Souza","year":"2010","journal-title":"Hum. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2017.04.009_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.10","article-title":"Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes","volume":"6","author":"Stevenson","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2017.04.009_bb0270","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/mp.2008.74","article-title":"Genomewide association for schizophrenia in the CATIE study: results of stage 1","volume":"14","author":"Sullivan","year":"2009","journal-title":"Mol. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2017.04.009_bb0275","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.tins.2013.06.002","article-title":"Protein tyrosine phosphatases PTPdelta, PTPsigma, and LAR: presynaptic hubs for synapse organization","volume":"36","author":"Takahashi","year":"2013","journal-title":"Trends Neurosci."},{"issue":"10","key":"10.1016\/j.schres.2017.04.009_bb0280","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.tcb.2013.07.004","article-title":"LAR-RPTPs: synaptic adhesion molecules that shape synapse development","volume":"23","author":"Um","year":"2013","journal-title":"Trends Cell Biol."},{"issue":"12","key":"10.1016\/j.schres.2017.04.009_bb0285","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrg2884","article-title":"Analysing biological pathways in genome-wide association studies","volume":"11","author":"Wang","year":"2010","journal-title":"Nat. Rev. Genet."},{"issue":"6","key":"10.1016\/j.schres.2017.04.009_bb0290","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1083\/jcb.201209132","article-title":"The adhesion protein IgSF9b is coupled to neuroligin 2 via S-SCAM to promote inhibitory synapse development","volume":"201","author":"Woo","year":"2013","journal-title":"J. Cell Biol."},{"issue":"10","key":"10.1016\/j.schres.2017.04.009_bb0295","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1523\/JNEUROSCI.6319-09.2010","article-title":"Synaptic localization and function of sidekick recognition molecules require MAGI scaffolding proteins","volume":"30","author":"Yamagata","year":"2010","journal-title":"J. Neurosci."},{"issue":"32","key":"10.1016\/j.schres.2017.04.009_bb0300","doi-asserted-by":"crossref","first-page":"E4579","DOI":"10.1073\/pnas.1602743113","article-title":"GCTA-GREML accounts for linkage disequilibrium when estimating genetic variance from genome-wide SNPs","volume":"113","author":"Yang","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.schres.2017.04.009_bb0305","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1073858410386384","article-title":"MAGUKs, synaptic development, and synaptic plasticity","volume":"17","author":"Zheng","year":"2011","journal-title":"Neuroscientist"},{"issue":"5","key":"10.1016\/j.schres.2017.04.009_bb0310","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ng.3538","article-title":"Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets","volume":"48","author":"Zhu","year":"2016","journal-title":"Nat. Genet."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417301962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417301962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:31:06Z","timestamp":1760297466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417301962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":62,"alternative-id":["S0920996417301962"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.04.009","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}